On-site reporting from other meetings and summits in the hematology/oncology arena.

Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis

Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML

COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis

CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?

Study Finds Thrombosis Risk Changes Throughout Myeloma Disease Course

Mogamulizumab May Be Effective in Relapsed/Refractory T-Cell Leukemia

SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

CASTOR Trial: Daratumumab Combination Doubles Response Rates in Myeloma Patients

TOURMALINE-MM3 and 4: Ixazomib as Maintenance Therapy in Myeloma Patients

For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”

Bortezomib Leads to More Complete Remissions in Patients With High-Risk Follicular Lymphoma

Ixazomib Plus Pomalidomide, Dexamethasone in Relapsed/Refractory Myeloma

Optimizing CAR T-Cell Therapy in Relapsed/Refractory ALL

ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients

SIRIUS: Promising Results for Daratumumab in Hard-to-Treat Myeloma Patients

Ruxolitinib in CMML: Study Shows Promising Results

Options for Treating the High-Risk APL Patient

PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape

back to top